Survival and progression to AIDS in a seroconverter cohort in the post-highly active antiretroviral therapy era: effectiveness goes on.
Progression to AIDS and death for 1129 HIV seroconverters from the GEMES cohort were analysed by calendar period (1996-1997, 1998-1999, 2000 onwards). A further hazard reduction was observed for a later period for both. Intravenous drug users (IDU) had a faster progression. The results highlighted the importance of monitoring the effectiveness of highly active antiretroviral therapy and to improve public health strategies directed to IDU to reduce inequity in HIV infection care.
Pérez-Hoyos
Santiago
S
Valencian School of Health Studies (EVES), Valencia, Spain.
Ferreros
Inma
I
del Amo
Julia
J
Muga
Roberto
R
del Romero
Jorge
J
de Olalla
Patricia Garcia
PG
Hernández-Aguado
Ildefonso
I
D000163:Acquired Immunodeficiency Syndrome / Q000401:mortality / Q000517:prevention & control*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018450:Disease Progression; D004812:Epidemiologic Methods; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D008297:Male; D013030:Spain / Q000453:epidemiology; D015819:Substance Abuse, Intravenous / Q000150:complications; D016896:Treatment Outcome